When my 14 y/o Twitter account was banned in 2024 after a hack, I lost all #meded posts. But in #slideshare, I found my 2017 presentation, the year after I started my off-label use of #sglt2i in kidney disease. I'm glad I got most things right back then
http://www.slideshare.net/chrisarg/sglt2-inhibitors-in-diabetic-kidney-disease
When my 14 y/o Twitter account was banned in 2024 after a hack, I lost all #meded posts. But in #slideshare, I found my 2017 presentation, the year after I started my off-label use of #sglt2i in kidney disease. I'm glad I got most things right back then
http://www.slideshare.net/chrisarg/sglt2-inhibitors-in-diabetic-kidney-disease
When my 14 y/o Twitter account was banned in 2024 after a hack, I lost all #meded posts. But in #slideshare, I found my 2017 presentation, the year after I started my off-label use of #sglt2i in kidney disease. I'm glad I got most things right back then www.slideshare.net/chrisarg/sgl...
@mikejohansenmd.medsky.social and myself said "class effect" 5 years ago when we put together a meta-analysis during the lockdowns pmc.ncbi.nlm.nih.gov/articles/PMC... My view of the economics of the #sglt2i from 4 years ago - worth considering the cost figure pmc.ncbi.nlm.nih.gov/articles/PMC...
actually #sglt2i may work in the absence of a RASi backbone at least as per EMPA-KIDNEY If we stick to the RASi requirement we will exclude the ~50% who cannot tolerate maximal RASi therapy (though ppl who give up after only 5mg of lisinopril are not my friends) #nephjc
It seems the usual #EBM suspects are making snarky comments about #CONFIDENCE similar to their comments about #flozins #sglt2i in the years leading up to CREDENCE/DAPA-CKD/EMPA-KIDNEY.
It was obvious then (and it is now) that they don't understand how UACR works as a biomarker
It seems the usual #EBM suspects are making snarky comments about #CONFIDENCE similar to their comments about #flozins #sglt2i in the years leading up to CREDENCE/DAPA-CKD/EMPA-KIDNEY. It was obvious then (and it is now) that they don't understand how UACR works as a biomarker
The results of #confidence were the best news today: combined treatment with #flozin #sglt2i and non steroidal #MRA cut by more than half the level of kidney damage markers (urine albumin/creatinine ratio). In every single trial to date cutting UACR has led to kidney protection
The results of #confidence were the best news today: combined treatment with #flozin #sglt2i and non steroidal #MRA cut by more than half the level of kidney damage markers (urine albumin/creatinine ratio). In every single trial to date cutting UACR has led to kidney protection
The evidence is strong for #SGLT2i and moderate for #GLP1RA (but note that the source data was only designed to infer the effects of the SGLT2i, not the GLP1RA in diabetic kidney disease). Note that combining the 2 drugs has an estimated benefit of .... 3/